Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis

BMC Cancer

Table 1 Main characteristics of including studies

study	year	place	design	Patients number		follow-up	Regimen^a			Age		Sex (male/female)
				PC	AC		PC group		AC group	PC	AC	PC	NC
				PC	AC		preoperative	postoperative	AC group	PC	AC	PC	NC
Yonemura	1993	Japan	RCT	29	26	3 years	PMUE	PMUE	PMUE	61.4 ± 8.34	56.4 ± 9.6	21/8	20/6
Kobayashi	2000	Japan	RCT	91	80	5 years	5′-DFUR	5′-DFUR + MMC	5′-DFUR + MMC	57.8	60.2	65/26	55/25
Nio	2004	Japan	RCT	102	193	7 years	UFT	UFT or FPEPIR + UFT	UFT or FPEPIR + UFT	63.5 ± 11.9	65.3 ± 11.5	70/32	141/52
Qu	2010	China	RCT	39	39	≥2 years	PTX + FOLFOX4	PTX + FOLFOX4 or ECF	PTX + FOLFOX4	NA	NA	26/13	22/17
X.Sun	2011	China	RCT	29	26	3 years	DCF	DCF	DCF	52.6 (33–72)		37/18
Z.Sun	2014	China	CCT	23	35	3 years	FOLFOX4	FOLFOX	FOLFOX	58 (34–79)	57 (31–80)	15/8	22/13
Feng	2015	China	CCT	80	90	Till discharge	SOX	SOX	SOX	61 (21–74)	59 (29–82)	63/17	71/19
Li	2012	China	CCT	33	37	≥ 5 years	FOLFOX	FOLFOX	FOLFOX	65 (41–75)	61 (27–78)	23/10	30/7
J.Zhang	2012	China	CCT	38	42	5 years	mFOLFOX7	mFOLFOX7 or mECF	mFOLFOX7	NA	NA	22/16	26/16
Nishioka	1982	Japan	CCT	64	59	5 years	5-FU	5-FU and MMP	5-FU and MMP	NA	NA	NA	NA
C.Zhang	2004	China	CCT	29	56	5 years	FAP or FMP	FAP or FMP	FAP or FMP	54.9 ± 12.9		69/22

PC perioperative chemotherapy, AC adjuvant chemotherapy, RCT randomized controlled trails, CCT clinical controlled trails
^aconcrete information of regimens is shown in Additional file 1

ISSN: 1471-2407